Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$25.06 - $34.09 $140,912 - $191,688
5,623 Added 51.91%
16,455 $466,000
Q4 2022

Feb 14, 2023

BUY
$24.98 - $39.77 $270,583 - $430,788
10,832 New
10,832 $316,000
Q2 2022

Aug 08, 2022

SELL
$41.26 - $51.35 $353,845 - $440,377
-8,576 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$44.58 - $52.6 $382,318 - $451,097
8,576 New
8,576 $424,000
Q1 2020

May 15, 2020

SELL
$34.37 - $60.07 $7,698 - $13,455
-224 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$54.32 - $64.31 $39,979 - $47,332
-736 Reduced 76.67%
224 $13,000
Q3 2019

Nov 14, 2019

BUY
$53.25 - $59.98 $27,477 - $30,949
516 Added 116.22%
960 $54,000
Q2 2019

Aug 14, 2019

BUY
$46.61 - $58.45 $16,033 - $20,106
344 Added 344.0%
444 $25,000
Q1 2019

May 15, 2019

BUY
$38.66 - $51.82 $3,865 - $5,182
100 New
100 $5,000

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $7.81M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.